The Company

Eurocine Vaccines has attracted internationally recognized experts to quest for the vaccines of tomorrow. Specialized in vaccine development, and with decades long experience, the highly qualified team has a proven record to manage all aspects of vaccine development including preclinical and clinical development, scalability into production, as well as business development and financing.

Today a publicly listed company situated close to the Karolinska Institutet, home of the Nobel Assembly.​

Read our story =>
Get to know our candidates =>
Learn more how we bridge the gap between innovation and market =>
For investors =>

Organisation

Team

CEO and Board Director

Dr. Hans Arwidsson

Dr. Hans Arwidsson is a former Air Force pilot with more than three decades of broad cross-functional executive experience from the pharmaceutical industry. Both from Big Pharma as AstraZeneca, and from several independent entrepreneurial companies, before joining Eurocine Vaccines. He holds a M.Sc. and a Ph.D. in pharmaceutical sciences from Uppsala University as well as an Executive MBA from Stockholm School of Economics.

Board

Chairman of the Board

Dr. Pierre A. Morgon

Today, Dr Morgon is a well acknowledged name with over 30 years of experience in the global pharmaceutical and biological industry. He has previously served at senior positions at e.g. ICI-Pharma, Synthelabo, Yamanouchi Pharma, BMS, Drug Abuse Sciences, Bio Alliance Pharma , Schering-Plough and Aventis Sanofi Pasteur. Today, a CEO, Chairman, Non-Executive Director and Advisor for a multitude of companies within the vaccine industry, as well as Regional Partner of Merieux Develeppement. Pierre A. Morgon holds a Doctorate of Pharmacy, a Master in Business Law and a MBA.

Non-Executive Director of the Board

Dr. Bengt Gustavsson

Dr. Bengt Gustavsson has held several leading positions in life science, both in large organizations such as Novartis and Sanofi-Aventis, and in smaller companies, e.g. Oncopeptides AB, and is now a consultant in medical affairs and clinical research. Bengt Gustavsson has been a non-executive board director in Nanexa AB and WntResearch AB. He holds a M.Sc. in pharmaceutical sciences and a Ph.D. in medical sciences, both from Uppsala University.

Non-Executive Director of the Board

Mr. Pär Thuresson

With a proven record as entrepreneur and businessman, Mr Thuresson is today the CEO and Board Director of the Industry Group Thuresson Sweden AB and a non-executive Director in several other companies.

President, CEO and Board Director

Dr. Hans Arwidsson

Please see Team above.